Trade Pluri Inc. - PLUR CFD

About Pluristem Therapeutics Inc.

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

Financial summary

BRIEF: For the six months ended 31 December 2021, Pluristem Therapeutics Inc. revenues was not reported. Net loss increased 6% to $22.4M. Higher net loss reflects General and administrative expenses increase of 30% to $4.8M (expense), Stock-based Compensation in SGA increase of 9% to $4.6M (expense), Research & Development Expense decrease of 75% to $72K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.82 to -$0.70.

Equity composition

Common Stock $0.00001 Par, 01/13, 100M auth., 58,333,206 issd. Insiders control 11.74%. IPO: NA. 11/07,1-for-200 reverse stock split. 11/07, Name changed from Pluristem Life Systems, Inc. 12/07, Exchanged changed from OTC Bulletin Board to NASDAQ.

Latest shares articles

Capital.com enhances EU client protection with $1 million insurance cover
Capital.com announced the launch of a new enhanced insurance scheme specifically for clients across the European Union (EU).
09:13, 26 June 2025
Buffett’s cash pile just got even larger
Buffett’s cash pile just got even larger
Warren Buffett just announced he's stepping down as CEO of Berkshire Hathaway – and he's leaving his successor a massive pile of cash. Since 2024, Buffett has sold off a massive amount of stock, more than doubling Berkshire's cash position from $167bn to $348bn.
18:05, 25 June 2025
Why the Federal Reserve is ignoring a major economic warning
Why the Federal Reserve is ignoring a major economic warning
Economic uncertainty is at an all-time high. It’s higher today than during the pandemic in 2020—and several times higher than during the Great Recession in 2008.
17:01, 25 June 2025
Oil price forecast 2025-2030: Third-party price target
Oil price forecast 2025-2030: Third-party price target
Discover third-party oil price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
16:03, 25 June 2025

Read our reviews to find out more about us

Read the feedback from our clients, whatever their experience level.
2024-10-22
i********

Very trustworthy and affordable for any size trades

2024-10-21
r******

It is very easy to connect with TradingView but the web interface is also great.

2024-10-15
j********

Easy to use and great support. Been using it for 2 years already and still happy

2024-10-14
D*****

Capital.com is one of the best stock trading platforms I’ve used. The UX and UI on both the mobile app and web platform are outstanding, making it incredibly easy to navigate. They’ve built a vibrant community of traders and investors, and their UAE team really stands out for delivering an exceptional trading experience.

2024-10-08
Y********

Best broker!! they call you to see if you need any help. The app is good and nice better than the rest

2024-10-04
I***** S******

Great app! I requested some features to be added, such as analysis tools, and they delivered. Amazing job! The agents are always helpful and reply quickly. It’s not 5 stars because, at times, some less experienced agents may say it’s impossible to fulfill the request or fix the problem while another agent, like Angel, quickly escalated the issue to the necessary team/person/department and resolved it

2024-10-04
M** S*

This is an excellent platform. The stop loss and take profit work very well; however, when the changes are very fast like at the beginning of the session, the stop loss does not work. If this defect is corrected it will be the perfect platform.

2024-09-30
a***********

-Nice -Easy to use - Beautiful Interface

2024-09-26
D*****

I think I'm new in this trading platform, but I find it affordable and most reliable. To be honest I'm not fully experienced trader, but with very limited knowledge of trading I try learn as much as I can by trying out different platforms see if can make money. My interests growing in you platform, l like news updates you also short videos on YouTube, other propaganda, poster and many more. I will see what happens in the coming months. Thanks capital team.

2024-09-26
J*** F******

Gives you options to start learning how too do it as it gives you a demo option to learn from your mistakes

2024-09-24
P******

Efficiency. When creating the account, it was smooth, efficient from start to finish. Verification of documents also was done the same day, unlike other platforms where you have to wait a day or two.

2024-09-04
O***** P***

From what I'm seeing it's cool Mixing it with trading view it's perfect... I didn't give it 5 star yet cos I still need to use it for some time

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

Join our community of traders worldwide
1. Create your account2. Make your first deposit3. Start trading